The chart above plots the price of MEDP over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 24 sessions over that window: $467.30 on 12 June 2026 through $538 on 17 July 2026.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 10, 2026
MEDP insider trades
SEC Form 4 · last 90 days · newest reported trade 27 Aug 2026
Open-market buys0
Open-market sells20
Net sold$82.62M
Non-trade filings7
DateInsiderTypeSharesValue
27 Aug 2026Troendle August J.President & CEOSell650$403K
26 Aug 2026Troendle August J.President & CEOSell4,000$2.48M
26 Aug 2026Kraft Robert O.DirectorSell3,858$2.38M
25 Aug 2026Troendle August J.President & CEOSell673$418K
24 Aug 2026Troendle August J.President & CEOSell1,983$1.23M
21 Aug 2026Troendle August J.President & CEOSell13,995$8.74M
20 Aug 2026Troendle August J.President & CEOSell27,174$16.81M
20 Aug 2026Brady Kevin M.CFO & TreasurerSell3,400$2.13M
19 Aug 2026Carley Brian TDirectorSell5,000$3.04M
19 Aug 2026DAVENPORT FRED B JRDirectorSell7,283$4.41M
19 Aug 2026Troendle August J.President & CEOSell15,609$9.47M
13 Aug 2026Troendle August J.President & CEOSell458$275K
Showing the 12 most recent of 20 open-market trades in this window. The figures above count all of them.
Compensation mechanics
Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
DateInsiderTypeSharesValue
26 Aug 2026Kraft Robert O.DirectorOption exercise3,858$325K
20 Aug 2026Brady Kevin M.CFO & TreasurerOption exercise3,400$472K
19 Aug 2026DAVENPORT FRED B JRDirectorOption exercise7,583$880K
07 Aug 2026McCarthy Cornelius P. IIIDirectorOption exercise3,858$325K
30 Jun 2026Carley Brian TDirectorOption exercise36
30 Jun 2026Kraft Robert O.DirectorOption exercise33
30 Jun 2026McCarthy Cornelius P. IIIDirectorOption exercise28
MEDP reported financials
SEC EDGAR XBRL
MEDP reported revenue of $2.5B for the fiscal year ended 31 Dec 2025. Net income over the same period was $451.1M.
FigureReportedPeriod
Revenue
$2.5B
31 Dec 2025 fiscal year
Net income
$451.1M
31 Dec 2025 fiscal year
Diluted EPS
$15.28
31 Dec 2025 fiscal year
Total assets
$2.1B
30 Jun 2026 at period end
Total equity
$433.9M
30 Jun 2026 at period end
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
MEDP earnings
SEC EDGAR
DatePeriodEPSRevenue
30 Jun 2026Q2 2026$4.25—
31 Mar 2026Q1 2026$4.28—
31 Dec 2025FY 2025$15.28—
30 Sep 2025Q3 2025$3.86—
30 Jun 2025Q2 2025$3.10—
31 Mar 2025Q1 2025$3.67—
31 Dec 2024FY 2024$12.63—
30 Sep 2024Q3 2024$3.01—
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
9 of the 45 institutional funds we track reported a MEDP position for the quarter ended 30 Jun 2026 — a combined $1.2B; the latest of those filings landed 02 Sep 2026.